Redeye is encouraged to learn that Moberg Pharma has completed the enrollment to the Phase 3 study f...
Redeye comments on Medivir's new early positive data from all patients in the study of fostrox + Len...
Incap downgraded its 2023 guidance on 5 October due to weaker-than-expected orders from its main cus...
Redeye is encouraged by the announcement that Nanexa’s clinical phase I trial with NEX-20 (NEX-20-01...
Another solid quarter awaits after the turnaround in Q4'22 Limited revisions - we forecast a resilie...
Reinitiating coverage, fair value range SEK 14-38 Q2: accelerating org.
Solteq’s near-term challenges continue and operative profitability is looking weak this year.
E&P in wins tender in collaboration with close partners No impact on financial guidance We currentl...
Equity analyst Markus Almerud makes a deep dive in electricity infrastructure, which is one of the m...
Sedan 2003 utvecklar och driver Mindark PE (”Mindark” eller ”Bolaget”) PC-spelet Entropia Universe.
Finepart meddelade under tisdagen den 3 oktober att bolaget initierar ett besparingsprogram.
Emission ger bolaget utrymme för tillväxt Irisity har under Q3 fått två kapitaltillskott, ett från b...
Intäkterna steg under kvartalet men resultatet tyngs som väntat av en begynnande kommersialiseringsf...
Redeye comments on the news that Dignitana has entered into a sales and marketing partnership with I...
With unpredictable energy prices and an urgent green transition, the need for energy efficiency meas...
Q3 report due Tuesday, 24 October Q3e: solid 6% org.
Redeye comments on the news that the first Medicare Administrative Contractor (MAC) has approved the...
Q3 report due on Thursday, 2 November Cost reductions taking effect Higher margins on new contracts ...
Redeye is encouraged that Lifeclean continues to get further validation of the PFAS remediation, thi...
Redeye initiates coverage of Circio (previously Targovax), which has a new focus on circular RNA tec...
